BOCA RATON, Fla., June 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializingin the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, will participate in
Mr. Sardano's participation will not be webcast, but a copy of the Company's corporate presentation is available in the Investors section of the Company's website at www.sensushealthcare.com.
About Sensus Healthcare Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio of treatment devices, the SRT-100 and SRT-100 Vision. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market. For more information, visit www.sensushealthcare.com.
Contact: LHA Investor Relations Kim Sutton Golodetz 212-838-3777 email@example.com
View original content:http://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-panel-discussion-at-the-cantor-fitzgerald-dermatology--aesthetics-summit-300664190.html
SOURCE Sensus Healthcare, Inc.
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All